↓ Skip to main content

American Association for Cancer Research

Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer

Overview of attention for article published in Molecular Cancer Therapeutics, April 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
1 news outlet
patent
2 patents

Citations

dimensions_citation
78 Dimensions

Readers on

mendeley
74 Mendeley
Title
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
Published in
Molecular Cancer Therapeutics, April 2018
DOI 10.1158/1535-7163.mct-17-0290
Pubmed ID
Authors

Neil O'Brien, Dylan Conklin, Richard Beckmann, Tong Luo, Kevin Chau, Josh Thomas, Ann Mc Nulty, Christophe Marchal, Ondrej Kalous, Erika von Euw, Sara Hurvitz, Colleen Mockbee, Dennis J. Slamon

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 74 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 11 15%
Researcher 9 12%
Student > Doctoral Student 5 7%
Student > Bachelor 4 5%
Other 4 5%
Other 11 15%
Unknown 30 41%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 17 23%
Medicine and Dentistry 7 9%
Agricultural and Biological Sciences 5 7%
Chemistry 4 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Other 5 7%
Unknown 33 45%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 November 2021.
All research outputs
#2,326,128
of 23,138,859 outputs
Outputs from Molecular Cancer Therapeutics
#274
of 3,882 outputs
Outputs of similar age
#51,135
of 325,560 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#11
of 56 outputs
Altmetric has tracked 23,138,859 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,882 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,560 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 56 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.